Digital Therapeutics

---

 Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high-quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions. Digital therapeutics form an independent category of evidence-based products within the broader digital health landscape, and are distinct from pure-play adherence, diagnostic, and telehealth products”. - Digital Therapeutics Alliance

At Acumen Health we offer a differentiated value offering by combining our expertise and capabilities in healthcare, biopharma, IT, big data and predictive analytics, machine learning and artificial intelligence to be at the forefront of both innovating and with the assistance of the operational implementation of digital therapeutics for current and emerging healthcare players. 

• The market size is forecasted to be $9 billion by 2025 
• In 2019, US digital health start-ups raised a total of $7.4—the second-largest funding year ever. Over 10 Digital-Biopharma deals representing >$450M in deal value1 in the last twelve months. Nearly 60% of active digital health investors in 2019 had previously made an investment in the sector
• Venture capital has invested across all stages (Seed to D+ and growth rounds); 62% of VCs were repeating investors in 2019, more than 50% of VCs have been repeating investors since 2014. 2/3 of the top 25 biopharma companies are developing digital programs in-house and over half have invested in outside digital programs

Reductions in cost due to reduced HCP visits and hospital burden

Improved clinical and health economic outcomes

Improvement in overall health and wellness and disease prevention

Proven safety profile and in instances of DTx replacement therapies no adverse events caused by pharmacological interventions

Positive incentives for single-payor systems, such as government schemes that provide insurance for life, absorb the long-term risks with patients so have an incentive to pay for therapies that may prevent them.

Augments where applicable current marketed therapeutics

For DTx replacement therapies, significantly reduces R&D costs

DTX solutions are within the pharma healthcare customer model so no significant infrastructure or commercialization costs 

Increased patient engagement especially earlier on in the cycle

 Patients are ever-more increasingly self-reliant and self-empowered

On-demand or easy access to treatment and care

Personalized treatment programs that use machine learning and AI to continuously update and tailor the software to meet the needs of the patient based on real-time data analytics

Increased access to evidence-based interventions

Encourages alternative solutions to pharmacological therapeutics to be considered thus expanding the digital health ecosystem

Reduces burden on HCPs and patients in costly and lengthy clinical trials

Catalyses the fragmented digital health ecosystem which has suffered from previous years of regulatory, legal and data security issues